News

Axios on MSN3d
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.
Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
Science-Based Medicine2dOpinion
Dr. Vinay Prasad is Now the Medical Establishment. It’s His Job to Run RCTs, and It’s Our Job to Call Him a Lying Piece of $#!& if He Fails.
From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...
MedPage Today on MSN3dOpinion
Vinay Prasad Speaks to CBER Staff: Which Prasad Showed Up?
The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
STAT3d
New CBER Director Vinay Prasad praises evidence, FDA reviewers in first speech to staff
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
BioPharma Dive3d
Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...